Marker Therapeutics (NASDAQ:MRKR) Upgraded at Brookline Capital Management

Marker Therapeutics (NASDAQ:MRKR) was upgraded by equities research analysts at Brookline Capital Management to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Separately, LADENBURG THALM/SH SH lifted their price target on Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Stock Down 9.9 %

Shares of Marker Therapeutics stock opened at $1.55 on Monday. Marker Therapeutics has a twelve month low of $1.55 and a twelve month high of $5.99. The firm’s 50-day moving average price is $2.92 and its 200 day moving average price is $3.25.

Insider Activity

In related news, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the acquisition, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. This trade represents a 51.73 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steve Elms acquired 11,085 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the transaction, the director now owns 325,370 shares of the company’s stock, valued at $1,041,184. This represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 17.35% of the company’s stock.

Institutional Investors Weigh In On Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. Invst LLC purchased a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned 0.22% of Marker Therapeutics at the end of the most recent reporting period. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.